Knees next for Mesoblast
Tuesday, 12 August, 2008
Preclinical trials conducted by Mesoblast [ASX: MSB] have shown that the company's adult stem cells are capable of regenerating damaged knee cartilage in a post-menopausal osteoarthritis large animal model.
A single injection of adult stem cells was able to repair and regenerate knee cartilage in ewes with well established osteoarthritis even though the cells were administered three months after initial joint damage.
This effect has yet to be demonstrated by any competing products on the market, the company said.
Mesoblast executive director Professor Silviu Itescu said the results meant the company would now target both post-menopausal and post-traumatic knee osteoarthritis for product commercialisation.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
